stock market research jobs

• Search Search Please fill out this field.
• Equity Research Analyst: The Job
• Career Paths
• Educational Qualifications
• Advanced Positions
• Additional Qualifications
• Equity Research Analyst FAQs

Equity Research Analyst: Career Path and Qualifications

Equity research analysts work for both buy-side and sell-side firms in the securities industry. They produce research reports, projections, and recommendations concerning companies and stocks. Typically, an equity analyst specializes in a small group of companies in a particular industry or country to develop the high-level expertise necessary to produce accurate projections and recommendations .

These analysts monitor market data and news reports and speak to contacts in the companies and industries they study to update their research daily.

Key Takeaways

• Equity research analysts work for both buy-side and sell-side firms in the securities industry producing research reports, projections, and recommendations surrounding companies and stocks.
• Most equity research analysts have a bachelor's degree in finance, accounting, economics, or business administration.
• Having a background in statistics and mathematics is beneficial for equity research analysts.
• Senior equity research analysts often have a master's degree. A Chartered Financial Analyst (CFA) designation, awarded by the CFA Institute, is recommended for analysts who want to move up the career ladder.

What Does an Equity Research Analyst Do?

In a buy-side firm—such as a wealth management firm , a pension fund, or a hedge fund—an equity research analyst typically supplies information and recommendations to the firm's investment managers, who oversee client investment portfolios and make final decisions about what securities to hold.

In a sell-side firm, such as a brokerage or a bank, an equity research analyst typically produces reports and recommendations for the firm's sales agents. The agents then go on to use the information to sell investments to their clients and the general public.

Analysts generally spend less time on financial modeling and more time writing reports and developing recommendations.

Career Paths in Equity Research

Most equity research analysts begin in entry-level research associate positions after completing bachelor's degree programs. Research associates work under the direction of a senior equity research analyst creating financial models and conducting research. New hires may work with a variety of analysts over the course of months as a general introduction to the job.

Most research associates are eventually assigned to a single working group covering a small group of firms. With more experience and excellent performance, associates can move directly into analyst positions, taking more active roles in the research process.

Educational Qualifications for an Equity Research Analysts

To work in equity research , a candidate must have a bachelor's degree, preferably in a relevant business discipline such as finance, accounting, economics, or business administration. Undergraduate degrees that provide in-depth quantitative training are also good options, including degrees in mathematics, statistics, engineering, and physics.

A master's degree is not required to advance into senior analyst positions. However, a master's degree in business administration or finance can help pave the way for career advancement, especially advancement into portfolio and fund management positions. 

Many equity research analyst positions require a license from FINRA.

Non-business majors should consider taking some courses in finance and other business disciplines if considering a career as an equity research analyst.

Advanced Positions in Equity Research

After several years of working in junior positions, some analysts return to school to earn master's degrees.

Although, high-performing analysts may continue into more senior research roles without returning to school. A senior equity research analyst who has a high degree of expertise in their specialty area can move into an investment management role overseeing a research team and an investment portfolio.

A portfolio manager is responsible for using the information supplied by equity research analysts and other staff to manage the mix of securities in a portfolio daily.

Other Qualifications for Equity Research Analysts

The preeminent professional qualification for equity research analysts and others working in securities research is the Chartered Financial Analyst (CFA) designation, which is awarded by the CFA Institute .

This designation requires candidates to have a minimum of 4,000 hours of qualifying experience. Consequently, it is generally considered a qualification for advancement into more senior positions in the field. The designation requires candidates to pass a series of three examinations.

Many equity research analysts require a license from the Financial Industry Regulatory Authority (FINRA) , a national body charged with oversight of securities firms and brokers. The licensing process typically requires sponsorship from an employing firm, so most analysts complete license requirements only after hiring is complete.

How Much Does an Equity Research Analyst Get Paid?

According to GlassDoor, the average salary for an equity research analyst in the U.S. in 2023 is $114,225.

How Many Hours per Week Can a Research Equity Analyst Expect to Work?

An equity research analyst can expect to work up to 60 hours per week on a typical week, which can increase to upwards of 80 hours per week during earnings season.

Who Do Equity Research Analysts Work for?

Equity research can be divided into sell-side and buy-side firms. Sell-side analysts work for investment banks and brokerages and research stocks in order to provide investment recommendations for their clients and the public. Buy-side analysts research stocks to identify investments for their own firm to invest in.

CFA Institute. " Become a Member ."

Financial Industry Regulatory Authority. " Standards for Admission ."

GlassDoor. " How Much Does an Equity Research Analyst Make? "

Mergers and Inquisitions. " The Equity Research Associate: Remnant of a Dying Industry, or the Hero That Gotham Deserves ."

• Terms of Service
• Editorial Policy
• Privacy Policy

Make Smarter, Data-Driven Investment Decisions

• Latest News
• Cryptocurrency
• U.S. Markets
• Europe & Middle East
• Emerging Markets
• Latin America
• Market Data
• Barron's
• Best New Ideas
• Mutual Funds
• Commodities
• Cryptocurrencies
• Financial Adviser Center
• Washington Watch
• Coronavirus
• The Federal Reserve
• Economic Report
• U.S. Economic Calendar
• Coronavirus Recovery Tracker
• The Moneyist
• Spending & Saving
• Credit Cards
• Real Estate
• Real Estate Listings
• Best New Ideas in Retirement
• Estate Planning
• Help Me Retire
• Social Security
• Retirement Calculator
• NewRetirement Planner
• Where Should I Retire
• Best Places
• How to Invest
• Virtual Stock Exchange
• MarketWatch 25 Years
• SectorWatch
• Getting to Work With
• Explainomics
• MarketBrief
• Fire Starters
• How Bad Is It
• The Cost of Things
• Office Hours
• Best New Ideas in Money Festival
• Mastering Your Money
• Live Events
• Leaderboard
• SwingTrader
• MarketSmith
• Newsletter Center
• Mortgage Calculator
• Multiple Quotes Tool
• Stock Screener
• Earnings Calendar
• Market Screener
• IPO Calendar
• Short Interest
• Trending Tickers Screener
• Premarket Screener
• Options Expiration Calendar
• After Hours Screener
• Currency Tools
• Mutual Fund Screener
• Upgrades & Downgrades
• Top 25 Mutual Funds
• Mutual Fund Comparison
• Economic Calendar
• Where Should I Retire?
• Retirement Planner
• Top 25 ETFs
• Personal Finance
• Account Settings

LIVE UPDATES | CONCLUDED

Stock Market Today: Dow ends down over 600 points to suffer worst day since early August after weak manufacturing reading

Follow all the latest u.s. market action for tuesday here..

Last Updated: 

Jobs report regains ‘crown’ as most important data for stocks, BofA chart shows

Christine Idzelis

Futures contracts for the S&P 500 index have become more sensitive to U.S. jobs reports than inflation readings, according to BofA Global Research.

The nonfarm payrolls report has “regained its crown as the most important data release for stocks,” BofA analysts said in a note dated Sept. 2. “All eyes will be on the August payrolls report this week,” they said, referring to the U.S. employment report that the Bureau of Labor Statistics will release on Friday.

S&P 500 futures inflation readings from the consumer-price index “than at any other point post-Covid, with the payrolls report now the bigger source of volatility,” according to their research. With inflation having eased considerably from its 2022 peak, investors are now watching the labor market closely for signs of softening.

The BofA chart below shows the reaction of the eMini S&P 500 Future Continuous Contract since August 2019 in the five minutes before the release of nonfarm-payrolls and the consumer-price-index data, through the 30 minutes after those reports came out, based on six-month averages.

(BOFA GLOBAL RESEARCH NOTE DATED SEPT. 2, 2024)

.css-10u2tr9-CardLink{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}.css-10u2tr9-CardLink.css-10u2tr9-CardLink:any-link{color:rgba(17,17,17,1);}.css-10u2tr9-CardLink.css-10u2tr9-CardLink:any-link:hover{color:rgba(54,119,168,1);-webkit-text-decoration:none;text-decoration:none;}.css-10u2tr9-CardLink.css-10u2tr9-CardLink.css-10u2tr9-CardLink *{cursor:inherit;} .css-16yayq8-CardLink{display:inline;color:var(--color-interactiveLink010);-webkit-text-decoration:none;text-decoration:none;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}@media screen and (prefers-reduced-motion: no-preference){.css-16yayq8-CardLink{transition-property:color,fill;transition-duration:200ms,200ms;transition-timing-function:cubic-bezier(0, 0, .5, 1),cubic-bezier(0, 0, .5, 1);}}@media screen and (prefers-reduced-motion: reduce){.css-16yayq8-CardLink{transition-property:color,fill;transition-duration:0ms;transition-timing-function:cubic-bezier(0, 0, .5, 1),cubic-bezier(0, 0, .5, 1);}}.css-16yayq8-CardLink svg{fill:var(--color-interactiveLink010);}.css-16yayq8-CardLink:hover:not(:disabled){color:var(--color-interactiveLink020);-webkit-text-decoration:underline;text-decoration:underline;}.css-16yayq8-CardLink:hover:not(:disabled) svg{fill:var(--color-interactiveLink020);}.css-16yayq8-CardLink:active:not(:disabled){color:var(--color-interactiveLink030);-webkit-text-decoration:underline;text-decoration:underline;}.css-16yayq8-CardLink:active:not(:disabled) svg{fill:var(--color-interactiveLink030);}.css-16yayq8-CardLink:focus-visible:not(:disabled){outline-color:var(--outlineColorDefault);outline-style:var(--outlineStyleDefault);outline-width:var(--outlineWidthDefault);outline-offset:var(--outlineOffsetDefault);}@media not all and (min-resolution: 0.001dpcm){@supports (-webkit-appearance: none) and (stroke-color: transparent){.css-16yayq8-CardLink:focus-visible:not(:disabled){outline-style:var(--safariOutlineStyleDefault);}}}.css-16yayq8-CardLink.css-16yayq8-CardLink:any-link{color:rgba(17,17,17,1);}.css-16yayq8-CardLink.css-16yayq8-CardLink:any-link:hover{color:rgba(54,119,168,1);-webkit-text-decoration:none;text-decoration:none;}.css-16yayq8-CardLink.css-16yayq8-CardLink.css-16yayq8-CardLink *{cursor:inherit;} .css-jjua3s-HeadlineTextBlock >*{display:inline-block;}.css-jjua3s-HeadlineTextBlock style[data-emotion]{display:none;} .css-v4nn77-HeadlineTextBlock{margin:0;font-family:Mulish,Helvetica,Arial,sans-serif;font-size:18px;line-height:20px;font-weight:800;letter-spacing:0px;font-style:normal;text-transform:none;font-stretch:normal;padding:0.5px 0px;}.css-v4nn77-HeadlineTextBlock::before{content:'';margin-bottom:-0.2211em;display:block;}.css-v4nn77-HeadlineTextBlock::after{content:'';margin-top:-0.1781em;display:block;}.css-v4nn77-HeadlineTextBlock >*{display:inline-block;}.css-v4nn77-HeadlineTextBlock style[data-emotion]{display:none;} Jobs report regains ‘crown’ as most important data for stocks, BofA chart shows

Futures contracts for the S&P 500 have become more sensitive to U.S. jobs reports than inflation readings, according to BofA Global Research.

S&P 500

SPX (S&P US)

E-Mini S&P 500

Copyright © 2024 MarketWatch, Inc. All rights reserved.

• Privacy Notice
• Cookie Notice

• MarketWatch
• Newsroom Roster
• MarketWatch Guides
• Copyright Policy
• Manage Notifications
• Cancel My Subscription
• Code of Conduct
• Corrections
• Reprints & Licensing
• Digital Self Service
• Your Ad Choices
• Corporate Subscriptions
• Accessibility
• Dow Jones Network
• The Wall Street Journal
• Investor's Business Daily
• Financial News London
• realtor.com
• Mansion Global
• Dow Jones Smart Money

Working together, we can reimagine medicine to improve and extend people’s lives.

Associate Director/Director PK Sciences - Oncology

About the role.

Key Responsibilities:

• Represent the PK Sciences function in project teams, interactions with stakeholders within the organization and interactions with regulatory agencies, as appropriate.
• Develop the PK strategy for lead optimization and oversee the execution of nonclinical studies to identify compounds with favorable DMPK properties.
• Work with teams to elucidate the understanding of PK/PD relationships and develop dosing strategies and predictions.
• Develop and execute clinical pharmacology strategies, including input into nonclinical and clinical study design, and analyzing PK and PK/PD data, to support compound development from discovery through late development.
• PK, dosimetry (radiopharmaceuticals), PK/PD and M&S component of study protocols, reports, project summaries and development plans, and author pharmacokinetic/clinical pharmacology/biopharmaceutics sections/radiation dosimetry of IND/IMPDs and NDA/BLAs as well as prepare appropriate responses to Health Authority questions across the globe.

This role reports to a PK Sciences (PKS) Oncology group lead/unit head within Translational Medicine (TM) in Biomedical Research. PKS is a global organization of about 300 associates, situated within Translational Medicine (TM), the clinical research arm of Biomedical Research within Novartis. PK Sciences plays a pivotal role in bringing innovative medicines to patients, by building on research advances to develop new therapies, bridging drug discovery and clinical application. PK Science is an enterprise-wide organization, working across both Biomedical Research and the Development organizations to advance the scientific knowledge of pharmacokinetics, metabolism and clinical pharmacology. Particularly, in radioligand therapies, Novartis has become the industry leader and is now developing a wide range of targeted radioligand therapies, and precision radioligand imaging agents, targeting multiple tumor types through a phenotypic precision medicine approach.

Minimum requirements:

• Ph.D. / Pharm.D. with relevant experience in clinical pharmacology, drug metabolism and pharmacokinetics or a related background.
• A minimum of 5 years of experience in drug discovery and/or development in a relevant environment (academia, CRO, biotech or Pharma).
• A minimum of 8 plus years of experience required to be considered for Director level including 5 plus years of experience in a lead role overseeing ADME/DMPK project strategy, either in discovery or clinical development.
• Extensive and in-depth knowledge of pharmacokinetics including, drug metabolism and PK/PD evaluation, experience in working in project teams (preferably global) as well as sound awareness of recent developments in drug development and regulatory sciences.
• Demonstrated success in working in a cross-functional, matrixed, project-team environment.
• Strong oral and written communication skills.
• Hands-on project experience with drug conjugates and/or radiopharmaceuticals is a plus.

This is a dual level posting. The final level and title of the offer role would be determined by the hiring team based on the skills, experience & capabilities required to perform the role at the level the role has been offered.

Benefits and Rewards:

Read our handbook to learn about all the ways we’ll help you thrive personally and professionally:  Novartis Life Handbook

Commitment to Diversity and Inclusion:

Novartis is committed to building an outstanding, inclusive work environment and diverse teams representative of the patients and communities we serve.

Novartis Compensation and Benefit Summary: The pay range for this position at commencement of employment is expected to be between $151,200-$226,800/year for Associate Director and $183,200 -$274,800/year for Director; however, while salary ranges are effective from 1/1/24 through 12/31/24, fluctuations in the job market may necessitate adjustments to pay ranges during this period. Further, final pay determinations will depend on various factors, including, but not limited to geographical location, experience level, knowledge, skills, and abilities. The total compensation package for this position may also include other elements, including a sign-on bonus, restricted stock units, and discretionary awards in addition to a full range of medical, financial, and/or other benefits (including 401(k) eligibility and various paid time off benefits, such as vacation, sick time, and parental leave), dependent on the position offered. Details of participation in these benefit plans will be provided if an employee receives an offer of employment. If hired, employee will be in an “at-will position” and the Company reserves the right to modify base salary (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance, Company or individual department/team performance, and market factors.

Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each other. Combining to achieve breakthroughs that change patients’ lives. Ready to create a brighter future together? https://www.novartis.com/about/strategy/people-and-culture

Join our Novartis Network: Not the right Novartis role for you? Sign up to our talent community to stay connected and learn about suitable career opportunities as soon as they come up: https://talentnetwork.novartis.com/network

Benefits and Rewards: Read our handbook to learn about all the ways we’ll help you thrive personally and professionally: https://www.novartis.com/careers/benefits-rewards

EEO Statement:

The Novartis Group of Companies are Equal Opportunity Employers who are focused on building and advancing a culture of inclusion that values and celebrates individual differences, uniqueness, backgrounds and perspectives. We do not discriminate in recruitment, hiring, training, promotion or other employment practices for reasons of race, color, religion, sex, national origin, age, sexual orientation, gender identity or expression, marital or veteran status, disability, or any other legally protected status. We are committed to fostering a diverse and inclusive workplace that reflects the world around us and connects us to the patients, customers and communities we serve.

Accessibility & Reasonable Accommodations

The Novartis Group of Companies are committed to working with and providing reasonable accommodation to individuals with disabilities. If, because of a medical condition or disability, you need a reasonable accommodation for any part of the application process, or to perform the essential functions of a position, please send an e-mail to [email protected] or call +1(877)395-2339 and let us know the nature of your request and your contact information. Please include the job requisition number in your message.

MoscowExchange

Moex chart , upcoming earnings, key stats , about moscowexchange, financials .

See all ideas  

Frequently Asked Questions

Stocks MOEX

Analyst Opinions for MOEX

MOEX Key Figures

Biggest Gainers

Biggest losers.